The NeurologyLive® neuromuscular disease clinical focus page offers updates and information related to the clinical care and management of individuals with neuromuscular diseases such as amyotrophic lateral sclerosis, Duchenne muscular dystrophy, cerebral palsy, and spinal muscular atrophy, as well as rare diseases. This page consists of news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, study and clinical trial findings, and more.
August 12th 2025
Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.
NeuroVoices: Pam Conley and Alan Glicklich, MD, on NVG-2089’s Potential to Treat CIDP
July 23rd 2025Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.
FDA Clears HyHub and HyHub Duo Devices for Easier Administration of Immune Globulin Infusion, Hyqvia
July 21st 2025The FDA-cleared duo devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more.
Rethinking Neurology Education With AI: A Preview of ANA/AUPN 2025
July 18th 2025Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.
How Simulations Can Improve Non-Clinical Competencies in Neurology Education
July 17th 2025Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.
Advancing Non-Opioid Neurosurgical Solutions for Refractory Pain Conditions
July 16th 2025Nester Tomycz, MD, director of neurosurgical pain division at Allegheny General Hospital, discussed emerging neurosurgerical approaches for chronic pain, with a focus on neuromodulation, patient selection, and non-opioid treatment pathways.
Late-Breaking Phase 2b PARADIGM Data Support Continued Development of PrimeC in ALS
July 14th 2025Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits.
European Commission Approves Efgartigimod Subcutaneous Injection for Forms of CIDP
June 24th 2025Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.